NUMETA G19% E EMULSION FOR INFUSION Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

numeta g19% e emulsion for infusion

baxter s.p.a., italy - alanine,arginine,aspartic acid,acetylcysteine,glutamic acid,glycine,histidine,isoleucine5,leucine,lysine,methionine,ornithine,phenylalanine,proline,serine,taurine,threonine,tryptophan,tyrosine,valine,sodium chloride,potassium acetate,calcium chloride,magnesium sulfate,sodium glycerophosphate,glucose,olive oil - emulsion for infusion - 1.83,1.92,1.37,0.43,2.29,0.91,0.87,1.53,2.29,2.51,0.55,0.57,0.96,0.69,0.91,0.41,0.85,0.46,0.81,1.74,1.79,3.14,0.56,0.55,2.21,191

AMINOPLASMAL 5% E WITHOUT CARBOHYDRATES SOLUTION F 5 %w/v Solution for Infusion Ireland - English - HPRA (Health Products Regulatory Authority)

aminoplasmal 5% e without carbohydrates solution f 5 %w/v solution for infusion

b. braun medical limited - isoleucine leucine lysine hydrochloride dl-methionine phenylalanine threonine tryptophan, l- valine arginine histidine aminoacetic acid alanine proline aspartic acid aspargine monohydrate acetylcysteine glutamic acid ornithine hydrochloride serine tyrosine sodium acetate trihydrate potassium acetate magnesium acetate tetrahydrate sodium dihydrogen phosphate dihydrate malic acid n-acetyltyrosine ph. eur. - solution for infusion - 5 %w/v

INTRAFUSIN 22 500 Unknown Solution for Infusion Ireland - English - HPRA (Health Products Regulatory Authority)

intrafusin 22 500 unknown solution for infusion

fresenius kabi limited - isoleucine leucine l-lysine-l-glutamate dihydrate l-methionine phenylalanine threonine tryptophan, l- valine arginine histidine acetylcysteine aminoacetic acid alanine glutamic acid proline serine n-acetyltyrosine ph. eur. - solution for infusion - 500 unknown

AMINOPLASMAL HEPA 10%-500ML GLASS BOTTLE Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

aminoplasmal hepa 10%-500ml glass bottle

b.braun medical industries sdn bhd - alanine; aspartic acid; isoleucine; glutamic acid; arginine; leucine; histidine; methionine; phenylalanine; proline; serine; threonine; tryptophan; valine; lysine acetate; acetylcysteine; glycine; n- acetyl- l- tyrosine; ornithine hcl; l-asparagine h²o -

AMINOPLASMAL 10% E WITHOUT CARBOHYDRATES SOLUTION 10 %w/v Solution for Infusion Ireland - English - HPRA (Health Products Regulatory Authority)

aminoplasmal 10% e without carbohydrates solution 10 %w/v solution for infusion

b. braun medical limited - leucine isoleucine lysine hydrochloride dl-methionine phenylalanine threonine tryptophan, l- valine arginine histidine aminoacetic acid alanine proline aspartic acid aspargine monohydrate acetylcysteine glutamic acid ornithine hydrochloride serine tyrosine sodium acetate trihydrate potassium acetate magnesium acetate tetrahydrate sodium phosphate monobasic malic acid n-acetyltyrosine ph. eur. - solution for infusion - 10 %w/v

ACETYLCYSTEINE solution United States - English - NLM (National Library of Medicine)

acetylcysteine solution

physicians total care, inc. - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 200 mg in 1 ml - acetylcysteine is the nonproprietary name for the n-acetyl derivative of the naturally occurring amino acid, l-cysteine. chemically, it is n-acetyl-l-cysteine. the compound is a white crystalline powder which melts in the range of 104° to 110°c and has a very slight odor. the structural formula of acetylcysteine is: c5 h9 no3 s                                                                                                      m.w.=163.19 acetylcysteine solution, usp is supplied as a sterile unpreserved solution (not for injection) in vials containing a 10% (100 mg/ml) or 20% (200 mg/ml) solution of acetylcysteine as the sodium salt. the inactive ingredients are edetate disodium, sodium hydroxide and sterile water for injection, usp. the ph of the solution ranges from 6.0 to 7.5. it is administered by inhalation or direct instillation for mucolysis, or orally for acetaminophen overdosage.

ACETYLCYSTEINE inhalant United States - English - NLM (National Library of Medicine)

acetylcysteine inhalant

cardinal health 107, llc - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 200 mg in 1 ml - acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) pulmonary complications of cystic fibrosis tracheostomy care pulmonary complications associated with surgery use during anesthesia post-traumatic chest conditions atelectasis due to mucous obstruction diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) acetylcysteine is contraindicated in those patients who are sensitive to it. acetylcysteine, administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. it is essential to initiate treatment as soon as possible after the overdose and, in any case, within 24 hours of ingestion. there are no contraindications to oral administration of acetylcysteine in the treatment of acetaminophen overdose.

ACETYLCYSTEINE inhalant United States - English - NLM (National Library of Medicine)

acetylcysteine inhalant

american regent, inc. - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 100 mg in 1 ml - acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) pulmonary complications of cystic fibrosis tracheostomy care pulmonary complications associated with surgery use during anesthesia post-traumatic chest conditions atelectasis due to mucous obstruction diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) acetylcysteine is contraindicated in those patients who are sensitive to it. acetylcysteine, administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. it is essential to initiate treatment as soon as po

ACETYLCYSTEINE solution United States - English - NLM (National Library of Medicine)

acetylcysteine solution

fresenius kabi usa, llc - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 100 mg in 1 ml - acetylcysteine solution, usp is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) pulmonary complications of cystic fibrosis tracheostomy care pulmonary complications associated with surgery use during anesthesia post-traumatic chest conditions atelectasis due to mucous obstruction diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) acetylcysteine is contraindicated in those patients who are sensitive to it. acetylcysteine solution, usp administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. it is essential to initiate trea

ACETYLCYSTEINE solution United States - English - NLM (National Library of Medicine)

acetylcysteine solution

hospira, inc. - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 100 mg in 1 ml - acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: chronic bronchopulmonary disease     (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) acute bronchopulmonary disease     (pneumonia, bronchitis, tracheobronchitis) pulmonary complications of cystic fibrosis tracheostomy care pulmonary complications associated with surgery use during anesthesia post-traumatic chest conditions atelectasis due to mucous obstruction diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) acetylcysteine is contraindicated in those patients who are sensitive to it. acetylcysteine, administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. it is essential to initiate treatment as soon as